创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

王丁丁, 戈晓爱, 成丽媛, 张雨建, 王涛. 糖皮质激素受体与新型糖皮质激素受体调节剂的研究进展[J]. 药学进展, 2023, 47(5): 392-附页4. DOI: 10.20053/j.issn1001-5094.2023.05.007
引用本文: 王丁丁, 戈晓爱, 成丽媛, 张雨建, 王涛. 糖皮质激素受体与新型糖皮质激素受体调节剂的研究进展[J]. 药学进展, 2023, 47(5): 392-附页4. DOI: 10.20053/j.issn1001-5094.2023.05.007
WANG Dingding, GE Xiaoai, CHENG Liyuan, ZHANG Yujian, WANG Tao. Research Progress of Glucocorticoid Receptor and New Glucocorticoid Receptor Modulators[J]. Progress in Pharmaceutical Sciences, 2023, 47(5): 392-附页4. DOI: 10.20053/j.issn1001-5094.2023.05.007
Citation: WANG Dingding, GE Xiaoai, CHENG Liyuan, ZHANG Yujian, WANG Tao. Research Progress of Glucocorticoid Receptor and New Glucocorticoid Receptor Modulators[J]. Progress in Pharmaceutical Sciences, 2023, 47(5): 392-附页4. DOI: 10.20053/j.issn1001-5094.2023.05.007

糖皮质激素受体与新型糖皮质激素受体调节剂的研究进展

Research Progress of Glucocorticoid Receptor and New Glucocorticoid Receptor Modulators

  • 摘要: 外源性糖皮质激素(GCs)在临床上广泛用于治疗炎症性疾病,其机制主要通过糖皮质激素受体(GR)发挥作用。但长期大量的使用GCs引起的不良反应使得GCs的使用受到限制,学术界正不断努力寻找更安全的GR调节剂。通过对GR的作用机制及长期使用GCs导致的不良反应进行介绍,同时,总结了近年来更安全的新型GR调节剂的研究进展,以期为新型GR配体的研发提供参考。

     

    Abstract: Exogenous glucocorticoids (GCs) are widely used in clinical treatment of inflammatory diseases, with their mechanism of action mainly through glucocorticoid receptor (GR). However, the use of GCs is limited by the adverse reactions caused by their longterm and large-scale application. The academic community is making continuous efforts to find safer GR regulators. This article introduces the mechanism of GR and the adverse reactions caused by long-term use of GCs, and summarizes the research progress of new safer GR modulators in recent years, in order to provide some reference for the development of new GR ligands.

     

/

返回文章
返回